Nettet5. nov. 2024 · Conclusions: Initial data from this Phase I study demonstrate that low doses of BCMA CAR-T cells manufactured by T-Charge TM in <2 days have encouraging clinical activity and a manageable safety profile in pts with r/r MM. PHE885 CAR-T cells expand rapidly in vivo, persist at relatively high levels for prolonged periods, and demonstrate a … Nettet3. des. 2024 · B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic review and meta-analysis was to determine its safety and clinical activity and to identify factors influencing these outcomes. We performed a database search using the …
Legend Biotech Showcases Updated and New Data from …
Nettet1. mar. 2024 · Legend Biotech is also advancing allogeneic CAR-T therapies, designed as off-the-shelf treatments, targeting CD20 and BCMA, as well as autologous CAR-T … Nettet5. nov. 2024 · Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy with 2 BCMA-targeting single-domain antibodies. In the phase 1b/2 CARTITUDE-1 study, cilta-cel demonstrated deep and durable responses in heavily pretreated pts with relapsed/refractory MM (Berdeja, Lancet , 2024). haltes bus 52
SEC Filing - Legend Biotech
NettetHere we conducted the clinical trial of a biepitope-targeting CAR T against B cell maturation antigen (BCMA) (LCAR-B38M) in 17 R/R MM cases. CAR T cells were i.v. infused after lymphodepleting chemotherapy. Two delivery methods, three infusions versus one infusion of the total CAR T dose, were tested in, respectively, 8 and 9 cases. Nettet5. des. 2024 · Bristol Myers Squibb and bluebird bio were first to file an anti-BCMA CAR-T for approval, but Johnson & Johnson and Legend Biotech are hot on their heels. Nettet5. des. 2024 · Bristol Myers Squibb and bluebird bio were first to file an anti-BCMA CAR-T for approval, but Johnson & Johnson and Legend Biotech are hot on their heels. haltes bus 17